Regeneron
Surveying great inventors and businesses
Axial: https://linktr.ee/axialxyz
Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company . We are excited to be in business with you — email us at info@axialvc.com
Regeneron is a biotech company delivering life-transforming medicines for serious diseases. Founded by physician-scientists over 30 years ago, they science-driven approach has led to nine FDA-approved medicines and eight EMA-approved medicines. Along with numerous product candidates in a range of diseases, including asthma, pain, cancer and infectious diseases.
Regeneron's discovery and development engine combines three unique strengths:
Genetics Center, one of the world's most advanced genetics institutes, is conducting groundbreaking research in genomics, genetic engineering, and immunology
VelociGene technology platform allows us to rapid discover of antibodies
A clinical development and commercialization organization that has successfully launched and marketed many of Regeneron’s medicines.
With recent achievements:
In 2020, Regeneron and its partner, Sanofi, developed and launched the first FDA-approved monoclonal antibody treatment for COVID-19
In 2018, Regeneron and its partner, Sanofi, launched Dupixent, a first-of-its-kind treatment for atopic dermatitis
In 2017, Regeneron and its partner, Merck, launched Praluent, a first-in-class treatment for high cholesterol
In 2016, Regeneron and its partner, Sanofi, launched EYLEA, a treatment for wet age-related macular degeneration